Shares of Nuvation Bio, Inc. (NUVB) surged 5.33% during Tuesday's intraday trading session, marking a significant upward movement for the healthcare stock.

The stock's rise appears to be driven by positive attention from Wall Street analysts. Multiple firms, including Wedbush and HC Wainwright & Co., have recently issued or maintained coverage on the company. Wedbush maintained its price target for Nuvation Bio at $11.00 per share, while HC Wainwright & Co. maintained its target at $17.00 per share.

Analyst ratings and price target assessments are closely watched by investors as indicators of a company's future prospects and valuation. The maintained targets from these firms, alongside broader analyst insights into the healthcare sector that included Nuvation Bio, likely contributed to increased investor confidence and buying activity during the session.